Influence of ABCC2, SLCO1B1, and ABCG2 polymorphisms on the pharmacokinetics of olmesartan

Journal of Cardiovascular Pharmacology

Volumn 60, Issue 1, 2012, Pages 49-54

  Kim, Choon O ^a   Cho, Sung K ^a   Oh, Eun S ^a   Park, Min S ^a   Chung, Jae Yong ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

Author keywords

BCRP; MRP2; OATP1B1; olmesartan; pharmacokinetics

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; OLMESARTAN; ORGANIC ANION TRANSPORTER 2;

ADULT; AREA UNDER THE CURVE; DRUG BLOOD LEVEL; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; SOUTH KOREA;

ADULT; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; ATP-BINDING CASSETTE TRANSPORTERS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; HUMANS; IMIDAZOLES; MALE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; ORGANIC ANION TRANSPORTERS; POLYMORPHISM, SINGLE NUCLEOTIDE; REPUBLIC OF KOREA; TETRAZOLES; YOUNG ADULT;

EID: 84863776220     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3182576098     Document Type: Review

References (23)

1. Wilford Germino F. Efficacy and safety of olmesartan medoxomil in patients with stage 1 hypertension: blood pressure lowering and goal achievement. Postgrad Med. 2010;122:57-67.
2. Lloyd Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:480-486.
3. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
4. Barrios V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig. 2007;27:545-558.
5. Laeis P, Pchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl. 2001;19:S21-S32.
6. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens. 2001;3:283-291.
7. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig. 2006;26:185-193.
8. Le MT, Pugsley MK, Vauquelin G, et al. Molecular characterisation of the interactions between olmesartan and telmisartan and the human angiotensin II AT1 receptor. Br J Pharmacol. 2007;151:952-962.
9. Zannad F, Fay R. Blood pressure-lowering efficacy of olmesartan relative to other angiotensin II receptor antagonists: an overview of randomized controlled studies. Fundam Clin Pharmacol. 2007;21:181-190.
10. Yamada A, Maeda K, Kamiyama E, et al. Multiple human isoforms of drug transporters contribute to the hepatic and renal transport of olmesartan, a selective antagonist of the angiotensin II AT1-receptor. Drug Metab Dispos. 2007;35:2166-2176.
11. Nakagomi Hagihara R, Nakai D, Kawai K, et al. OATP1B1, OATP1B3, and mrp2 are involved in hepatobiliary transport of olmesartan, a novel angiotensin II blocker. Drug Metab Dispos. 2006;34:862-869.
12. Miura M, Satoh S, Inoue K, et al. Telmisartan pharmacokinetics in Japanese renal transplant recipients. Clin Chim Acta. 2009;399:83-87.
13. Laechelt S, Turrini E, Ruehmkorf A, et al. Impact of ABCC2 haplotypes on transcriptional and posttranscriptional gene regulation and function. Pharmacogenomics J. 2011;11:25-34.
14. Suwannakul S, Ieiri I, Kimura M, et al. Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism. J Hum Genet. 2008;53:899-904.
15. Gandelman K, Fung G, Messig M, et al. Systemic exposure to atorvastatin between asian and caucasian subjects: a combined analysis of 22 studies. Am J Ther. 2010. (Epub ahead of print).
16. U.S. Food and Drug Administration. Drug Approval Package: Benicar (Olmesartan Medoxomil) Tablets. US Food and Drug Administration, Silver Spring, MD, 2011.
17. Smith BP, Vandenhende FR, DeSante KA, et al. Confidence interval criteria for assessment of dose proportionality. Pharm Res. 2000;17: 1278-1283.
18. U.S. Food and Drug Administration. Guidance for Industry: Bioavailability and Bioequivanece Studies for Orally Administered Drug Products-General Considerations. US Food and Drug Administration, Center for Drug Evaluation and Research, Silver Spring, MD, 2003.
19. Suzuki H, Sugiyama Y. Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv Drug Deliv Rev. 2002;54:1311-1331.
20. Ho WF, Koo SH, Yee JY, et al. Genetic variations of the ABCC2 gene in the Chinese, Malay, and Indian populations of Singapore. Drug Metab Pharmacokinet. 2008;23:385-391.
21. Ufer M, von Stulpnagel C, Muhle H, et al. Impact of ABCC2 genotype on antiepileptic drug response in Caucasian patients with childhood epilepsy. Pharmacogenet Genomics. 2011;21:624-630.
22. Ieiri I, Higuchi S, Sugiyama Y. Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs. Expert Opin Drug Metab Toxicol. 2009;5:703-729.
23. Sun N, Sun X, Chen B, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol. 2010;65:437-446.